Treatment of idiopathic anaphylaxis with dupilumab: a case report
Abstract Background Anaphylaxis is an acute, potentially life-threatening allergic reaction that typically occurs after exposure to a trigger, while idiopathic anaphylaxis (IA) occurs in the absence of a trigger. Acute management of both triggered anaphylaxis and IA relies on the use of epinephrine....
Main Authors: | Elizabeth Pepper, Luke Pittman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13223-023-00838-8 |
Similar Items
-
Cold urticaria with risk of anaphylaxis treated with omalizumab: a case report
by: Tonatiuh Ramses Bedolla-Pulido, et al.
Published: (2021-02-01) -
Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
by: Changhua Zhu, MD, et al.
Published: (2023-02-01) -
COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01) -
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
by: Anthony F. LaCava, et al.
Published: (2023-08-01) -
Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review
by: Petra Staubach, et al.
Published: (2022-02-01)